CMS head Slavitt jabs drug companies

Playing off outrage over increases in the price of EpiPen from Mylan N.V. (NASDAQ:MYL), acting CMS Administrator Andy Slavitt has taken to Twitter to call for drug price transparency.

On Wednesday, Slavitt's account linked to a story that said EpiPen's price had "quietly" risen 400% since 2007, and appended a suggestion: "How about we find a way for prices not to rise so 'quietly?'" ...